Public Companies
Field Trip Health & Wellness To Webcast Live at the KCSA Mental Health Conference on December 15th
Field Trip Health & Wellness Ltd. (TSXV: FTHW), a global leader in the delivery of psychedelic therapies, today announced that Ronan Levy, Chairman…

Field Trip Health & Wellness Ltd. (TSXV: FTHW), a global leader in the delivery of psychedelic therapies, today announced that Ronan Levy, Chairman & Chief Executive Officer of Field Trip Health & Wellness, will webcast live at the KCSA Mental Health Conference, hosted by VirtualInvestorConferences.com, on Thursday, December 15th, 2022.
DATE: December 15, 2022
TIME: 11:00 a.m. ET
LINK: https://bit.ly/3Ub0iE3
A recording of the webcast presentation will be available on the Events and Presentations section of Field Trip’s investor relations website following the events.
The Field Trip management team will also participate in one-on-one investor meetings following the conference. For institutional investors to schedule a meeting, please contact fieldtripIR@kcsa.com.
Recent Company Highlights
- Provided a business update and reported fiscal second quarter 2023 results.
- Launched Freedom by Field Trip™, a first-of-its-kind one-year hybrid ketamine therapy program that blends the power of psychedelic-assisted therapies with holistic wellness support.
- Announced the relaunch and refresh of its award-winning psychedelic app, now named Field Trip.
- Strengthened leadership team with two executive appointments.
About Field Trip Health & Wellness Ltd
With a large global community of psychedelic-interested people, proprietary psychedelic therapies that generate transformative results for people in the treatment of mental health conditions and a brand and share of voice that is reaching millions of people, Field Trip is a center of gravity for the psychedelic renaissance.

-
Psilocybin10 hours ago
Microsoft brings OpenAI’s DALL-E image creator to the new Bing
-
Psilocybin7 hours ago
Are Psychedelics a New Paradigm or Business as Usual?
-
Psilocybin6 hours ago
Lucy Scientific Acquires Psychedelic Assets from Wesana Health
-
Markets & Investing4 hours ago
Tom McDonald, CEO of Clerkenwell Health, Sits in the Investor Hotseat on March 30th
-
Psilocybin4 hours ago
First Patient Dosed in Europe in Clairvoyant’s Phase 2b Clinical Trial Exploring Psilocybin Therapy as a Treatment for Alcohol Use Disorder
-
DMT4 hours ago
New Study Gives Most Advanced View of the Brain on Psychedelics